Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18 years of age or older~* Sexually active female subjects of child-bearing potential must agree to use an effective method of birth control during the treatment and follow-up period~* Required to sign an informed consent form~* Subjects attending physician agrees to provide care following FMT~* Able to follow study procedures and follow-ups.~* Diagnosed by medical history of ≥ 3 RCDAD bouts in outpatients or ≥ 2 bouts of RCDAD in an inpatient with ≥ 2 positive fecal tests for C. difficile toxin~* Received at least one course of adequate antibiotic therapy for CDAD (≥ 10 days of vancomycin, metronidazole or fidaxomicin) after the subjects last bout of CDAD~Exclusion Criteria:~* Subjects with known neutropenia with absolute neutrophil count \<0.5 x 109/L~* Evidence of toxic megacolon, fulminant colitis, gastrointestinal perforation, ileus, abdominal distension, lack of bowel sounds, fever, or hypotension~* Known peripheral white blood cell count \> 15.0 x 109/L or temperature \> 38.0 °C~* Diarrhea due to definable non-CDAD pathogen~* Post total colectomy or presence of a colostomy~* Unable to tolerate FMT via enema for any reason~* Requiring systemic non-C. difficile antibiotic therapy at the time of FMT~* Actively taking Saccharomyces boulardii or other probiotic at the time of FMT~* Need for continuing use of oral vancomycin, oral or IV metronidazole, fidaxomicin, rifaximin or nitazoxanide at the time of FMT~* Severe underlying disease such that the patient is not expected to survive for one or more years or unstable medical condition requiring daily change in treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Frozen Microbiota (Type: ACTIVE_COMPARATOR): Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
- Lyophilized Microbiota (Type: ACTIVE_COMPARATOR): Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).